Meeting
2019 ASCO Annual Meeting
Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tolerability, in patients with solid tumors.
Authors
Jaffer A. Ajani
The University of Texas MD Anderson Cancer Center, Houston, TX
Jaffer A. Ajani , Milind M. Javle , Cathy Eng , David R. Fogelman , Barry Douglas Anderson , Chun Zhang , Kenzo Iizuka
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT02171221
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3034)
DOI
10.1200/JCO.2019.37.15_suppl.3034
Abstract #
3034
Poster Bd #
26
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Bosutinib in combination with pemetrexed in patients with selected metastatic solid tumors: A phase I study (NCT03023319).
First Author: Nagla Fawzy Abdel Karim
Poster
2014 ASCO Annual Meeting
A phase I study to assess the safety, tolerability, and PK of dovitinib (D) in combination with gemcitabine (G) and capecitabine (C) in patients with advanced solid tumors.
First Author: Gerald J. Fetterly
Poster
2013 Breast Cancer Symposium
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James
Poster
2013 ASCO Annual Meeting
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James